Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Highlights,Zacks Research adjusted its Q2 2025 EPS estimate for Sanofi to $0.93, slightly decreasing from a prior prediction ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Sanofi now said the agreement follows completion ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

Allworth Financial LP grew its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 28.4% during the fourth quarter, HoldingsChannel reports. The firm owned 6,524 shares of the company’s ...

Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The vaccine ...

Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ...

Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...

Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

Sanofi SA (NASDAQ:SNY) and Johnson & Johnson (NYSE:JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine ...